A Phase III, Open-Label, Multicenter, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of LM-108 in Combination With Toripalimab Versus Paclitaxel Injection as Second-Line Therapy for CCR8-Positive Locally Advanced or Metastatic Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 03 Feb 2026
At a glance
- Drugs LM-108 (Primary) ; Toripalimab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Sponsors LaNova Medicines Limited
Most Recent Events
- 03 Feb 2026 New trial record